On Friday, Moleculin Biotech Inc (NASDAQ: MBRX) was -7.66% drop from the session before, before settling in for the closing price of $0.5. A 52-week range for MBRX has been $0.25 – $3.65.
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 26.36%. When this article was written, the company’s average yearly earnings per share was at 80.33%. With a float of $45.11 million, this company’s outstanding shares have now reached $49.50 million.
Moleculin Biotech Inc (MBRX) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Moleculin Biotech Inc stocks. The insider ownership of Moleculin Biotech Inc is 8.87%, while institutional ownership is 0.87%. The most recent insider transaction that took place on Jun 23 ’25, was worth 100,000. In this transaction Chief Financial Officer of this company bought 270,270 shares at a rate of $0.37, taking the stock ownership to the 287,587 shares. Before that another transaction happened on Jun 23 ’25, when Company’s CEO and President bought 675,675 for $0.37, making the entire transaction worth $250,000. This insider now owns 743,607 shares in total.
Moleculin Biotech Inc (MBRX) Earnings and Forecasts
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -2.85 earnings per share (EPS) during the time that was less than consensus figure (set at -2.44) by -0.41. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.26 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 80.33% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 45.64% during the next five years compared to 26.36% growth over the previous five years of trading.
Moleculin Biotech Inc (NASDAQ: MBRX) Trading Performance Indicators
You can see what Moleculin Biotech Inc (MBRX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.15.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.59, a number that is poised to hit -0.26 in the next quarter and is forecasted to reach -1.05 in one year’s time.
Technical Analysis of Moleculin Biotech Inc (MBRX)
Compared to the last year’s volume of 4.41 million, its volume of 3.37 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 63.88%.
During the past 100 days, Moleculin Biotech Inc’s (MBRX) raw stochastic average was set at 24.91%, which indicates a significant decrease from 53.55% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0385 in the past 14 days, which was lower than the 0.0646 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5206, while its 200-day Moving Average is $0.9371. Nevertheless, the first resistance level for the watch stands at $0.5021 in the near term. At $0.5426, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.5861. If the price goes on to break the first support level at $0.4181, it is likely to go to the next support level at $0.3746. Should the price break the second support level, the third support level stands at $0.3341.
Moleculin Biotech Inc (NASDAQ: MBRX) Key Stats
There are 49,499K outstanding shares of the company, which has a market capitalization of 22.85 million. As of now, sales total 0 K while income totals -21,760 K. Its latest quarter income was 0 K while its last quarter net income were -7,640 K.
